By
Ottobock has reported a solid start to 2026, with first-quarter revenue rising to €396.0 million for the January–March period, compared with €382.8 million in the same period last year. The company said organic core revenue growth reached 5.1%, supported by continued demand for high-quality prosthetic and neuro-orthotic solutions.
The quarterly statement points to a business that continues to expand despite regional variation, currency headwinds and a strong comparative period in Q1 2025. Ottobock confirmed its full-year 2026 guidance, expecting organic core revenue growth of 5.0% to 8.0% and an underlying core EBITDA margin above 26.5%.
Prosthetics and Neuro-Orthotics Remain Key Growth Drivers
Ottobock’s core revenue increased to €378.4 million, up from €362.6 million in Q1 2025. The company highlighted prosthetics and neuro-orthotics as key contributors, with products such as Genium X4, Kenevo and C-Brace continuing to support growth momentum.
For orthotic and prosthetic professionals, the statement underlines the continued commercial importance of advanced mobility technologies, especially microprocessor-controlled prosthetic knees, neuro-orthotic systems and patient-care services. The report also notes that first Genium X4 deliveries in Ukraine contributed to growth in the EMEA region.
EMEA Leads Regional Performance
EMEA remained Ottobock’s largest region, accounting for 74.5% of total revenue in the first quarter of 2026. Revenue in the region increased by 7.4% to €295.0 million, compared with €274.6 million in Q1 2025.
APAC also delivered growth, with revenue rising 5.2% to €28.2 million, supported by strong organic growth in both B2B and B2C activity and additional revenue from the acquisition of Northern Prosthetics in Australia.
The Americas reported revenue of €72.8 million, down from €81.4 million in the previous year. Ottobock attributed the decline mainly to negative foreign exchange effects, softer order intake from a large US customer, and the unusually strong Q1 2025 performance following the launch of Genium X4 and reimbursement expansion for Kenevo in K2-level amputees.
B2B Products and Patient Care Both Contribute
Products and components, Ottobock’s B2B segment, remained the largest revenue category, generating €213.5 million in Q1 2026. This represented 53.9% of total core revenue and reflected 5.5% organic growth.
Patient care, the company’s B2C business, grew by 6.1% to €164.8 million. This was driven by organic growth in the Americas and APAC, as well as the acquisitions of Matton Orthopedie in Belgium and Northern Prosthetics in Australia.
Profitability Improves
Ottobock also reported improved profitability. Gross profit increased to €206.5 million, while gross margin improved to 52.1%, compared with 50.9% in the prior-year period. The company said the improvement was driven mainly by mix effects and slightly lower purchasing costs from procurement initiatives.
Underlying core EBITDA rose to €84.3 million, up from €75.5 million in Q1 2025. The underlying core EBITDA margin improved to 22.3%, compared with 20.8% one year earlier. Underlying net income increased to €22.6 million, while free cash flow rose significantly to €41.5 million.
Innovation Pipeline Ahead of OT World 2026
Ottobock said it plans to launch the next wave of innovation at OT World in Leipzig in May 2026. For the global O&P sector, OT World remains one of the most important platforms for prosthetics, orthotics, rehabilitation technology and clinical education.
The company also reported a strategic investment in Blue Arbor Technologies, Inc., a company focused on human-machine interfaces. This signals continued interest in technologies that may shape future prosthetic control, rehabilitation interfaces and assistive mobility systems.
Paralympic Winter Games Technical Support
Beyond financial performance, Ottobock highlighted its role as official technical service partner for the Paralympic Winter Games Milano Cortina 2026. The company said it supported the event with an 86-strong technical service team on site in Italy.
This technical service role remains an important visibility platform for the company, demonstrating the practical repair, adjustment and support infrastructure required to keep athletes competing at elite level.
Why This Matters for the O&P Industry
Ottobock’s Q1 2026 results suggest that demand for advanced prosthetic and neuro-orthotic technologies remains resilient, particularly in EMEA and APAC. The growth of both B2B products and patient-care services also reflects the wider direction of the global O&P market: manufacturers are not only supplying components, but increasingly shaping integrated care, service delivery and innovation ecosystems.
For clinicians, technicians, distributors and rehabilitation providers across IMEA, the results point to several important trends:
- Advanced prosthetic knees and neuro-orthotic systems continue to drive commercial momentum.
- Patient-care networks remain an important growth area for large O&P manufacturers.
- APAC and EMEA remain central to global expansion.
- Human-machine interface technologies are likely to become increasingly relevant to future prosthetic and orthotic innovation.
- Major industry events such as OT World continue to be used as launch platforms for next-generation mobility solutions.
- Ottobock
- OT World
- Genium X4
- Kenevo
- C-Brace
- Paralympic Winter Games Milano Cortina 2026
